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Abstract
Antigen-based therapies (ABTs) very effectively prevent the development of type 1 diabetes (T1D) when given to young
nonobese diabetic (NOD) mice, however, they have little or no ability to reverse hyperglycemia in newly diabetic NOD mice.
More importantly, ABTs have not yet demonstrated an ability to effectively preserve residual ß-cells in individuals newly
diagnosed with type 1 diabetes (T1D). Accordingly, there is great interest in identifying new treatments that can be
combined with ABTs to safely protect ß-cells in diabetic animals. The activation of c-aminobutyric acid (GABA) receptors
(GABA-Rs) on immune cells has been shown to prevent T1D, experimental autoimmune encephalomyelitis (EAE) and
rheumatoid arthritis in mouse models. Based on GABA’s ability to inhibit different autoimmune diseases and its safety
profile, we tested whether the combination of ABT with GABA treatment could prolong the survival of transplanted ß-cells
in newly diabetic NOD mice. Newly diabetic NOD mice were untreated, or given GAD/alum (20 or 100 mg) and placed on
plain drinking water, or water containing GABA (2 or 6 mg/ml). Twenty-eight days later, they received syngenic pancreas
grafts and were monitored for the recurrence of hyperglycemia. Hyperglycemia reoccurred in the recipients given plain
water, GAD monotherapy, GABA monotherapy, GAD (20 mg)+GABA (2 mg/ml), GAD (20 mg)+GABA (6 mg/ml) and GAD
(100 mg)+GABA (6 mg/ml) about 1, 2-3, 3, 2-3, 3-8 and 10-11 weeks post-transplantation, respectively. Thus, combined GABA
and ABT treatment had a synergistic effect in a dose-dependent fashion. These findings suggest that co-treatment with
GABA (or other GABA-R agonists) may provide a new strategy to safely enhance the efficacy of other therapeutics designed
to prevent or reverse T1D, as well as other T cell-mediated autoimmune diseases.
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Introduction
Antigen-based therapies for autoimmune disease are theoreti-
cally appealing because they can induce regulatory responses with
little adverse side-effects. When given to young NOD mice ABTs
can effectively prevent the development of T1D. ABTs, however,
have little or no ability to slow disease progression after NOD mice
develop mild hyperglycemia. In human clinical trials, ABT’s have
not yet shown a significant ability to preserve residual insulin-
producing ß-cells in individuals newly diagnosed with T1D. In
light of these results, it is widely thought that the most promising
future therapeutic approach to preserve residual ß-cells after T1D
onset will be through a combination of treatments that induce
different beneficial mechanisms [1].
We have shown that T cells express GABAA receptors (GABAA-
Rs) that can be modulated pharmacologically in the same way as
GABAA receptors on neurons [2]. We demonstrated that GABA
administration after the onset of insulitis effectively inhibited the
development of T1D long-term in NOD mice [3]. Additionally, a
GABAA-R agonist that can pass through the blood brain barrier
ameliorated EAE after its onset in SJL mice [4]. Recently, we
showed that GABA consumption through drinking water
effectively reduced the frequency and severity of collagen-induced
arthritis in DBA1/J mice [5], and that GABA consumption can
inhibit the development of obesity-related inflammation [6]. Thus,
GABA treatment can inhibit pathogenic immune responses in
different animal models of autoimmune disease that are mediated
by different mechanisms, which occur in mice with different
genetic backgrounds. This, together with GABA’s safety for
human consumption, makes GABA an excellent candidate for
testing in combination with ABTs.
NOD mice often progress from mild to severe hyperglycemia
within 1-2 weeks, but it takes about 10–14 days for ABTs to induce
maximal immune responses to the administered autoantigen, and
even longer for regulatory T cell responses to then spread to other
ß-cell autoantigens (reviewed in [7]). Consequently, by the time
ABT-induced regulatory responses peak in NOD mice, insufficient
ß-cell mass remains and the treatments appear ineffective.
However, we, and others, have shown that ABTs using GAD
can induce regulatory responses after T1D onset in NOD mice, as
evidenced by their ability to prolong the survival of syngenic islet
grafts in NOD mice [8,9]. In these studies, diabetic NOD mice
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were treated with GAD, maintained on insulin, and several weeks
later, the mice were implanted with syngenic islets, thereby
allowing sufficient time for the induction and spreading of
regulatory responses. Thus, ABT can induce regulatory responses
in diabetic NOD mice and these responses can be assessed using a
syngenic islet transplantation model. We therefore used this model
to assess whether combining ABT with GABA treatment could
better protect transplanted ß-cells in diabetic animals than each
monotherapy.
Materials and Methods
All studies were approved by the UCLA Chancellor’s Animal
Research Committee (approval #2000-023-33). Human GAD65
(Diamyd Medical, Stockholm) was complexed with alum (Pierce
Biotechnology, Rockford, Ill.) as per manufacturer’s instructions.
Female NOD mice (Taconic Farms) were maintained in a specific
pathogen-free facility. After the NOD mice developed hypergly-
cemia (blood glucose .300 mgs/dL on two consecutive days) they
were randomly assigned to a treatment group. Mice were, or were
not, immunized intraperitoneally with GAD/alum (20 mg or
100 mg) and given plain drinking water or water containing
GABA (2 or 6 mg/ml, Sigma-Aldrich catalog #A2129). Fresh
drinking water was provided weekly. After 14 days, the mice were
revaccinated with the same dose of GAD/alum. Mice were given a
minimal amount of insulin (,1.5 units/day) to maintain their
blood glucose levels ,400 mg/dL. Twenty–eight days after the
first treatment, we transplanted 12–13 pancreases from newborn
NOD.scid mice under their kidney capsule and insulin treatment
was discontinued. Their blood glucose was monitored 3 times per
week. Two readings .250 mgs/ml of glucose was considered as
the recurrence of hyperglycemia. The extent to which each
treatment restored normoglycemia was analyzed by the log rank
test. A p,0.05 was considered statistically significant.
Results
The dynamic changes in the concentration of blood glucose in
individual mice within each treatment group after transplantation
are shown in Fig. 1. The newborn pancreas grafts reversed
hyperglycemia in 100% of the recipient mice. Control transplant
recipients became diabetic again about 1 week after receiving the
graft, as expected. Mice given GAD/alum (100 mg) monotherapy
became diabetic again about 2-3 weeks after transplantation
(Fig. 1A) which is a significantly longer period of normoglycemia
than that in the control group (p,0.005). Similarly, mice given
GABA (6 mg/ml) alone become diabetic again about 3 weeks after
transplantation (Fig. 1B, p,0.005 compared to control group).
Thus, both GABA and GAD monotherapies can prolong
normoglycemia after syngenic pancreas implantation in the
absence of immunosuppressants.
Mice that received a combination of low dose GAD/alum
(20 mg) with low dose GABA (2 mg/ml) became hyperglycemic 2–
3 weeks after receiving the grafts (Fig. 1D, p,0.005 compared to
untreated). Although this combined therapy prolonged normogly-
cemia compared to that in mice that only received a graft, this
therapy had similar efficacy to GAD/alum (100 mg) and GABA (6
mg/ml) monotherapies. Interestingly, mice that received low dose
GAD/alum (20 mg) together with a higher GABA dose (6 mg/ml)
became diabetic sporadically 3-8 weeks post-implantation (Fig. 1E,
p,0.01 vs. low dose GAD/alum+low dose GABA). All mice given
GAD/alum (100 mg)+GABA (6 mgs/ml) remained normoglyce-
mic for 10-11 weeks post-transplantation (Fig. 1F, p,0.005 vs.
GAD/alum (20 mg)+GABA (6 mg/ml). Therefore, while GAD
(100 mg) monotherapy and GABA monotherapy (6 mgs/ml) each
had a modest but significant beneficial effect, the combination of
these treatments acted synergistically to promote longer normo-
glycemia.
Discussion
While ABTs are a theoretically appealing strategy to promote ß-
cell tolerance, they have not yet demonstrated the ability to
preserve residual ß-cells in newly diabetic individuals. Accordingly,
there is great interest in combining ABT with other safe treatments
in order to more effectively down-regulate pathogenic autoim-
mune responses. Based on the ability of GABA treatment to inhibit
autoimmune processes in mouse models of T1D, EAE and
rheumatoid arthritis, and its safety for human consumption, we
tested it in combination with an ABT for their ability to protect
transplanted ß-cells from autoimmune-mediated rejection in
diabetic mice.
We found that monotherapy using GABA or GAD/alum
significantly prolonged the survival of transplanted syngenic ß-cells
in diabetic NOD mice. While mice that received implants alone
remained normoglycemic only about 1 week after transplantation,
mice treated with either monotherapy remained euglycemic for
about 3 weeks following islet transplantation. Its worth pointing
out that while oral GABA monotherapy at 6 mgs/ml had a modest
ability to delay the recurrence of hyperglycemia, oral GABA at just
2 mgs/ml was sufficent to very effectively inhibit disease
development in the collagen-induced arthritis mouse model [5].
Second, the therapeutic efficacy of GAD (100 mg) in alum was less
than that of GAD (100 mg) in incomplete Freund’s adjuvant (IFA)
which we tested in a previous study using the same syngenic islet
transplantation protocol in newly diabetic NOD mice [8].
Immunization with antigen in both alum and IFA leads to
vigorous humoral responses to the antigen in mice, but IFA
induces five-fold greater Th2 cell responses than alum to the same
antigen [10]. Notably, the magnitude of the ABT-induced Th2
response is directly related to their therapeutic efficacy in NOD
mice [7,11], which is likely to explain the greater efficacy of GAD/
IFA compared to GAD/alum. Moreover, the magnitude of the
ABT-induced Th2 response determines the extent of Th2
spreading to other ß-cell autoantigens which generates additional
regulatory responses that can far outnumber those to the
administered autoantigen itself [7,11]. These observations suggest
that optimizing adjuvants for ABTs may be critical for inducing
effective regulatory responses in human clinical trials.
Combination therapy with a low dose of GAD/alum (20 mg)
and GABA (2 mg/ml) had a beneficial effect relative to controls,
but it’s effect was similar to that of a higher dose of either
monotherapy. In contrast, all mice treated with combined GAD/
alum (100 mg) and GABA (6 mg/ml) remained euglycemic for 10-
11 weeks, suggesting a dose-dependent effect. The period of
normoglycemia in graft recipients given this combined therapy
was about three-fold longer than in graft recipients given either
monotherapy, indicating that ABT and GABA have synergistic
beneficial effects.
Combined therapy did not permanently reverse hyperglycemia.
However, the therapeutic efficacy compares well with a previous
study of combination EGF and gastrin that also used a model of
syngenic islet transplantation in diabetic NOD mice and observed
that the median time to recurrence of hyperglycemia was about 8
weeks [12]. Pathogenic autoimmune responses in individuals
newly diagnosed with T1D, and particularly those with latent
autoimmune diabetes in adults (LADA), may be much less
aggressive than those in diabetic mouse model that we have
studied. Since ABTs and GABA treatments do not induce
Combining Antigen Therapy with GABA Treatment
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leukopenia and have no known side-effects, the combination of
GABA or other GABA-R agonists with various ABTs are excellent
candidates for testing in human clinical trials.
The results indicate that treatment with 100 mg, but not 20 mg,
GAD/alum induces significant beneficial effects in diabetic NOD
mice (Fig. 1F vs. 1E). Based on a very small dosing study of
immunization with GAD/alum to preserve insulin production in
individuals with LADA [13], a 20 mg GAD/alum dose was
selected for further study in newly diabetic individuals. While this
treatment showed initial promise in preserving residual ß-cells in
those newly diagnosed with T1D in phase II studies [14], a larger
phase III study did not observe a therapeutic effect [15]. Our
Figure 1. Synergistic effects of combined GAD/alum+GABA treatment to prolong transplanted syngenic ß-cell survival in diabetic
NODmice. After the onset of hyperglycemia mice were, or were not, immunized with GAD/alum (20 or 100 mg, twice) and given drinking water that
contained 0, 2 or 6 mg/ml GABA. Mice were maintained on a low amount of insulin until islet transplantation. Twenty-eight days after initiating
treatment, the mice received newborn NOD.scid pancreases under their kidney capsule and insulin treatment was discontinued. Lines show
longitudinal blood glucose levels of individual mice post-transplantation. Dashed line indicates blood glucose of 250 mgs/dL. A) No treatment, B)
GAD/alum (100 mg) alone, C) GABA (6 mg/ml) alone, D) GAD/alum (20 mg)+GABA (2 mg/ml), E) GAD/alum (20 mg)+GABA (6 mg/ml), and F) GAD/alum
(100 mg)+GABA (6 mg/ml).
doi:10.1371/journal.pone.0025337.g001
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observations concerning the lack of efficacy of low-dose GAD in
alum underscore the need for more basic studies of ß-cell antigen
dose and adjuvants in humans to help translate ABTs to the clinic.
Islet cells also express GABA-Rs [16,17,18,19,20]. In vitro studies
with isolated islets suggested that GABA could promote islet cell
replication [19]. More recent studies indicate that GABA can
indeed promote ß-cell replication ([20] and our unpublished
observations). However, we do not think that GABA’s beneficial
effects are primarily through promoting ß-cell replication or
modulating islet cell function (e.g., inhibiting glucagon secretion)
because 1) transplanted ß-cells are very rapidly destroyed if
autoimmune responses are not inhibited (Fig. 1A) and 2) treatment
with GABA alone has only a small beneficial effect (Fig. 1C).
Accordingly, we believe that GABA’s major beneficial effects in
this model are through modulating immune cell function.
The protective mechanisms induced by ABTs have been widely
studied and can involve the induction of regulatory T cell
responses such as Th2, Th3, Tr1 and Tregs (reviewed in [7,21]).
GABA has been shown to inhibit TCR-activated T cell cycling
[3]. The opening of T cell GABAA-R Cl
- channels leads to
depolarization, which should modulate the influx of Ca2+ through
mitogen-activated Ca2+ channels and thereby inhibit TCR-
activated T cell cycling [3,22,23]. In our studies of collagen-
induced arthritis in mice we observed that GABA treatment
reduced collagen-reactive Th1 responses and reduced collagen-
reactive IgG2a (but not IgG1 antibodies, consistent with reduced
Th1 help) [5]. Additionally, the activation of GABAA-Rs on APC
leads to decreased phosphorylation of p38 MAPK and p44/42
ERKs and reduced production of inflammatory cytokines in vitro in
response to LPS [4]. Finally, we, and others, have recently shown
that GABA treatment increases the frequency of Tregs in vivo
[6,20]. Since one or more of the GABA treatment-induced
protective mechanisms are distinct from the protective mecha-
nisms evoked by other T1D immunotherapeutics that are
currently under study, GABA or other GABA-R agonists, are
excellent candidates for use in combined therapies to achieve
synergistic beneficial effects.
In regards to the safety of GABA treatment, we have observed
in past studies that long-term GABA treatment did not
significantly alter the total numbers of splenic mononuclear cells
and percentages of CD4+, CD8+, T and B lymphocytes [3], nor
did it desensitize autoreactive T cells to GABA-mediated
inhibition [5]. Thus, unlike immunodepletive treatments, GABA
administration does not reduce the naı¨ve T cell pool that is needed
for ABT to prime antigen-specific regulatory T cells. Long-term
oral GABA treatment was tested in the 1950s–1980s in human
clinical trials for its ability to reduce epileptic seizures and
ameliorate cerebrovascular disorders in hundreds of individuals
[24,25,26]. The results showed no adverse effects, but no clinical
benefit, which may because GABA has little ability to cross the
blood brain barrier. GABA has been sold for many years over the
counter as a nutraceutical with the unsupported claim that it acts
as a sleep aide.
Pharmaceutical interests have focused on drugs that can get
through the blood brain barrier and modulate GABA-Rs in the
central nervous system. The inability of GABA to get through the
blood brain barrier makes it an ideal candidate to modulate
peripheral GABA-Rs without CNS side effects. Additionally,
identifying other GABA-R ligands that do not efficiently cross the
blood brain barrier and have better pharmokenetic features may
be of value for the treatment of autoimmune and other
inflammatory diseases.
Human immune cells express GABAA-Rs [27] and GABA
inhibits human PBMC inflammatory responses in vitro (our
unpublished observations). The combined ABT and GABA
therapeutic strategy should be extendable to other ß-cell antigens
(e.g., proinsulin and HSP277) and to other modes of antigen
delivery (e.g., inhalation and DNA). GABA or other GABA-R
agonists may also enhance the beneficial effects of other
therapeutic approaches. Finally, the therapeutic strategy presented
here can be extended to other T cell-mediated autoimmune
diseases.
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